- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00215917
D-Serine Monotherapy for Schizophrenia
N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic medication, has reduced negative, depressive, and cognitive symptomatology. We will be investigating the effect of D-serine, (DSR), a selective and potent NMDAR agonist, as monotherapy for treatment resistant schizophrenics.
40 subjects on stable doses of risperidone will be randomized under double-blind conditions into a treatment group, which will receive D-serine 2100 mg, or a control group, which will continue to receive risperidone. Treatment will continue for 14 weeks.
Symptoms and side effects will be rated biweekly with the CGI, PANSS, BPRS, SAS, AIMS, and UKU. Before and after the trial subjects will undergo neuropsychological assessments. Baseline and post-trial levels of amino acids relevant to glutamatergic neurotransmission (glutamate, glutamine, aspartate, glycine, serine, alanine) will be assessed.
The primary outcome measures of the study will be the PANSS total scores and the positive and negative symptom cluster scores.
Study Overview
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91351
- Recruiting
- Herzog Hospital, Department of Psychiatry
-
Contact:
- Pesach Lichtenberg, M.D.
- Phone Number: 972-2-5316929
- Email: licht@cc.huji.ac.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- DSM-IV criteria for chronic schizophrenia
- Treatment resistant
- aged 18-70
- Two months on stable risperidone dose
- PANSS positive symptom cluster score >20
- PANSS negative symptom cluster score >22
Exclusion Criteria:
- Substance abuse
- Concurrent DSM IV axis I disorder
- Serious medical disorder
- Concurrent drug therapy that can obscure the effect of risperidone or DSR.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pesach Lichtenberg, M.D., Herzog Hospital, and Hadassah Medical School--the Hebrew University of Jerusalem, Israel
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- lichtenberg1CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on D-serine 2100 mg daily
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedAtopic DermatitisUnited States
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Kowa Company, Ltd.Completed
-
Coopervision, Inc.Completed
-
Manal AbdelmalekCompletedNonalcoholic SteatohepatitisUnited States
-
Basilea PharmaceuticaCompletedUrothelial CarcinomaUnited Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
-
Eli Lilly and CompanyCompletedGlioblastoma MultiformeGermany
-
Johnson & Johnson Pharmaceutical Research & Development...Withdrawn
-
Kowa Company, Ltd.Completed
-
University of PittsburghNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedOsteoporosis | Bone Loss | Fragility FracturesUnited States